Subtype
Extranodal NK-/T-Cell Lymphoma, Nasal Type
CI-CAN-00009487Explore in graph →
Hematologic2 active trials
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00009487Explore in graph →
Clinical trials
23 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04414163 | A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type | active not recruiting | Phase 2 | 23 | ImmuneOncia Therapeutics Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05475925 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | recruiting | Phase 1 / Phase 2 | 200 | Dren BioINDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT03493451 |
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms |
| completed |
| Phase 2 |
| 77 |
| BeiGeneINDUSTRY |
| 5 |
| Oct 26, 2024 |
| clinicaltrials |
| NCT04509466 | Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL | terminated | Phase 1 / Phase 2 | 41 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04602065 | Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial | terminated | Phase 1 / Phase 2 | 9 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT04676789 | Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL(SPENT) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT03363555 | SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma | unknown | Phase 2 | 97 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 18, 2020 | clinicaltrials |
| NCT04405375 | GPED Regimen for Relapsed/Refractory or Advanced ENKTCL | unknown | Phase 2 | 29 | Beijing Tongren HospitalOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04338282 | Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma | unknown | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 0 | Apr 8, 2020 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT01991158 | GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2016 | clinicaltrials |
| NCT02229682 | Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Sep 30, 2014 | clinicaltrials |
| NCT00901147 | Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma | completed | Phase 2 | 25 | Singapore General HospitalOTHER | 3 | Jun 27, 2014 | clinicaltrials |
| NCT01921790 | Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Aug 22, 2013 | clinicaltrials |
| NCT01667289 | Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma | terminated | Phase 2 | 4 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01667302 | Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials